NASDAQ : XRTX

XORTX Therapeutics Inc. — Company profile

Healthcare · Biotechnology · Canada

Last price 1 USD (Oct 30, 2026, 4:00 PM EDT) · Market cap 1.82M

Overview · Financial statements · Key statistics · Dividends · Company profile · Price history · Reports

Company profile

XORTX Therapeutics Inc., a late-stage clinical pharmaceutical company, engages in the development and commercialization of therapies to treat hyperuricemia related diseases in Canada. It develops XRx-026, which is in Phase III for the treatment of gout; XRx-008, which is in Phase II for the treatment of autosomal dominant polycystic kidney disease; XRx-101, which is in Phase II for the treatment of acute kidney injury associated with respiratory virus infection, including sepsis and coronavirus; and XRX-225, which is in preclinical stage for the treatment of type 2 diabetic nephropathy, as well as VB4-P5, a program for the treatment and prevention of fibrosis in the kidney. The company is based in Calgary, Canada.

Details

NameXORTX Therapeutics Inc.
SectorHealthcare
IndustryBiotechnology
Employees3
Founded2011
CeoAllen Davidoff
CountryCanada
ExchangeNASDAQ
Fiscal YearJanuary - December
Reporting CurrencyUSD
IsinCA98420Q4051
Cusip98420Q405
Cik0001729214
Sic2834
Share ClassClass A Shares

Key executives

NameTitle
Mika GrassoCo-Chief Executive Officer and Director
Dr. Allen Warren Davidoff Ph.D.Founder, Co-Chief Executive Officer, President and Director
Dr. Michael Scott Bumby D.V.M., M.B.A.Chief Financial Officer
Dr. Stephen Haworth M.D., MRCPChief Medical Officer
Dr. Stacy Evans M.B.A., M.D.Chief Business Officer
Nick RigopulosDirector of Communications
Dr. David Sans M.B.A., Ph.D.Director of Corporate Development
Dr. David MacDonald Ph.D.Consultant of Clinical Operations
Charlotte MayCorporate Secretary

Contact

Address3710 - 33rd Street NW, Calgary, AB T2L 2M1, Canada
Phone403 455 7727
Websitehttps://www.xortx.com